Objectives: To investigate the use of statins and acetylsalicylic acid (ASA) in HIV people in clinical practice. Design: A multicenter, nationwide, prospective cohort study, including 1182 consecutive HIV patients was conducted. Methods: Statin and ASA prescription was evaluated in primary and secondary cardiovascular disease prevention, according to the European AIDS Clinical Society (EACS) guidelines. Results: Followed-up patients (998) were mostly males (70.9 %) with a mean age at enrolment of 46.5 years (SD 9.5). The mean time of follow-up was 3.3 years (SD 0.8). At the last follow-up visit, statins would have been recommended for 31.2 % and ASA for 16 % by EACS guidelines. Conversely, only 15.6 and 7.6 % of patients were on statin and ASA treatment, respectively; only 50.3 % of patients treated with statins achieved recommended low-density lipoprotein cholesterol (LDL-c) levels. At the last follow-up visit, agreement between statin therapy and EACS recommendation was 0.58 (95 % CI 0.52–0.63). The corresponding figure for ASA therapy was 0.50 (95 % CI 0.42–0.58), whereas the agreement for ASA therapy in secondary prevention was 0.59 (95 % CI 0.50–0.68). Conclusions: The prescription of statins and ASA in HIV-infected patients remains largely suboptimal, as only about 50 % of patients requiring statins and ASA are properly treated. Higher attention on this relevant issue and further investigation are warranted in this at risk population.
Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice : the results from HIV-HY study / G.V. De Socio, E. Ricci, G. Parruti, L. Calza, P. Maggi, B.M. Celesia, G. Orofino, G. Madeddu, C. Martinelli, B. Menzaghi, L. Taramasso, G. Penco, L. Carenzi, M. Franzetti, P. Bonfanti. - In: INFECTION. - ISSN 0300-8126. - 44:5(2016 Oct), pp. 589-597. [10.1007/s15010-016-0893-z]
Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice : the results from HIV-HY study
L. Taramasso;
2016
Abstract
Objectives: To investigate the use of statins and acetylsalicylic acid (ASA) in HIV people in clinical practice. Design: A multicenter, nationwide, prospective cohort study, including 1182 consecutive HIV patients was conducted. Methods: Statin and ASA prescription was evaluated in primary and secondary cardiovascular disease prevention, according to the European AIDS Clinical Society (EACS) guidelines. Results: Followed-up patients (998) were mostly males (70.9 %) with a mean age at enrolment of 46.5 years (SD 9.5). The mean time of follow-up was 3.3 years (SD 0.8). At the last follow-up visit, statins would have been recommended for 31.2 % and ASA for 16 % by EACS guidelines. Conversely, only 15.6 and 7.6 % of patients were on statin and ASA treatment, respectively; only 50.3 % of patients treated with statins achieved recommended low-density lipoprotein cholesterol (LDL-c) levels. At the last follow-up visit, agreement between statin therapy and EACS recommendation was 0.58 (95 % CI 0.52–0.63). The corresponding figure for ASA therapy was 0.50 (95 % CI 0.42–0.58), whereas the agreement for ASA therapy in secondary prevention was 0.59 (95 % CI 0.50–0.68). Conclusions: The prescription of statins and ASA in HIV-infected patients remains largely suboptimal, as only about 50 % of patients requiring statins and ASA are properly treated. Higher attention on this relevant issue and further investigation are warranted in this at risk population.File | Dimensione | Formato | |
---|---|---|---|
De Socio, Infection 2016.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
610.61 kB
Formato
Adobe PDF
|
610.61 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
s15010-016-0893-z.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
593.4 kB
Formato
Adobe PDF
|
593.4 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.